Tricyclic antidepressants — TCAs — are among the most effective antidepressants ever developed. They are also among the most dangerous. Their efficacy is real and well established; their side effect burden is substantial; their lethality in overdose is what removed them from first-line use. Today, they survive in specific niches, and those niches are worth knowing.
- Class
- Tricyclic Antidepressants
- Mechanism
- SERT + NET reuptake inhibition (varies by drug) PLUS H1 antihistamine, M1 anticholinergic, alpha-1 adrenergic blockade
- Typical dose
- Highly variable by drug; nortriptyline 25-150 mg, clomipramine 50-250 mg
- Half-life
- ~12-30 hours typically
- FDA indications
- MDD; clomipramine for OCD; many off-label uses (chronic pain, neuropathic pain, migraine prophylaxis, insomnia at low doses)
- Key adverse effects
- Anticholinergic burden (significant in older adults), sedation, weight gain, orthostatic hypotension, cardiac conduction effects (QRS widening), lowered seizure threshold. Lethal in overdose (~10x therapeutic dose can be fatal).
- Representative agents
- Amitriptyline, nortriptyline, imipramine, clomipramine, doxepin, desipramine
Black box: Suicidal thinking/behavior in pediatric and young adult patients
Largely supplanted by SSRIs/SNRIs for first-line depression treatment due to side effects and overdose risk. Modern niches: treatment-resistant depression, neuropathic pain, migraine prophylaxis, OCD (clomipramine specifically), low-dose insomnia (doxepin).
The TCA mechanism is "dirty" — a polite pharmacology term for "binds many things." At therapeutic doses, a TCA blocks SERT and NET (the antidepressant effect), and also blocks H1 receptors (causing sedation), M1 muscarinic receptors (causing anticholinergic effects — dry mouth, constipation, blurred vision, urinary retention, cognitive impairment), and alpha-1 adrenergic receptors (causing orthostatic hypotension). Different TCAs lean toward different parts of this profile. Nortriptyline is among the least anticholinergic; amitriptyline is among the most sedating; clomipramine is the most serotonergic and the most effective for OCD.
Tricyclic antidepressants are the original mixed-mechanism agents — effective but burdened by the off-target receptor activity that defines their side-effect and toxicity profile.
Mechanism note: TCAs remain effective antidepressants and analgesics, but the off-target receptor activity — anticholinergic, antihistaminergic, alpha-blocking, sodium-channel — makes them second-line and dangerous in overdose.
Overdose lethality is the defining concern. Roughly ten times the therapeutic dose can be fatal. The mechanism of death is cardiac — TCAs are sodium channel blockers in addition to everything else, and toxic doses produce QRS widening, conduction abnormalities, and arrhythmias. Seizures occur. Anticholinergic delirium occurs. Severe hypotension occurs. Treatment is supportive — sodium bicarbonate for QRS widening, intubation for airway protection, ICU care. There is no specific antidote.
In an era when most depressed patients can be effectively treated with safer agents, prescribing a class that is reliably lethal in overdose to a population with elevated suicide risk is a serious choice. That's the simple reason TCAs are no longer first-line.
- Cost
- Most TCAs generic: $4-15/month (many on $4 lists).
- Generic status
- All major TCAs generic for decades.
- Formulary typical
- Tier 1 generics. No PA.
- Access friction
- Cheap and available. Doxepin 3-6 mg (Silenor) is brand-only and expensive (~$150/month); generic doxepin caps (10 mg minimum) often crushed/divided.
Prescriber tip: For niche uses (clomipramine OCD, nortriptyline pain, low-dose doxepin sleep), pharmacy access is rarely the issue — overdose risk is. Limit dispensing in suicide-risk patients.
But they are not extinct. Several specific situations still favor TCAs.
Clomipramine for OCD — often the most effective single agent in severe OCD, sometimes outperforming SSRIs. Used as monotherapy or combined with SSRI for refractory cases. The serotonergic effect drives the OCD benefit.
Nortriptyline or amitriptyline for chronic neuropathic pain. Decades of evidence support TCAs at lower doses (often 25-75 milligrams) for diabetic neuropathy, postherpetic neuralgia, chronic low back pain, fibromyalgia. The pain effect appears at doses below the antidepressant threshold and is independent of mood improvement.
Migraine prophylaxis — amitriptyline at low doses is established. Topiramate and propranolol compete for first-line, but TCAs remain in the toolkit.
Low-dose doxepin (3-6 milligrams) for insomnia. At doses far below the antidepressant range, doxepin is a highly selective H1 antagonist with minimal anticholinergic or daytime sedation effects. It's an effective non-controlled sleep aid that the rest of the doxepin dose range cannot match.
When you encounter a patient on a TCA, the question is rarely "should this be a TCA?" and more often "is the TCA serving this specific clinical purpose well?" If it is — established responder, niche indication, careful overdose risk assessment — leave it alone. If it isn't, the alternatives are usually available.